Evren Technologies Selected as BioPitch Semifinalists for the 2019 BioFlorida Conference

Gainesville, FL – October 2, 2019 –

Evren Technologies Inc. has been selected to compete at the BioPitch Semifinals at the 2019 BioFlorida Conference.

Evren Technologies was selected from a large field of quality applicants and will compete with 15 of Florida’s top Life Science companies at the closed-door sessions of the BioFlorida Conference. These 16 companies will present their businesses to a panel of investors and attempt to secure a spot in finals and present at the general session.

“We are thrilled to be named semifinalist for this year’s BioPitch,” said Blythe Karow, President and COO of Evren Technologies. “We have made great strides in the development of the Phoenix™ and we can’t wait to share our progress.”

The initial closed-door presentations will take place Monday, October 21 at the BioFlorida Conference in Tampa. The finalists will present again the following morning at the general session on October 22.

In addition to the BioPitch competition, the 22nd Annual BioFlorida Conference will feature executives and thought leaders that drive Florida’s life science industry. The conference takes place from October 20-22 at the Tampa Marriott Water Street.

 

 About BioFlorida Technologies

BioFlorida represents 6,200 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors that collectively employ 87,000 Floridians.

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

About Evren Technologies

Evren Technologies, founded in 2018, is a privately-held medical device company headquartered in Newberry, Florida, near the University of Florida.  Evren’s mission is to advance the treatment of PTSD and other psychological disorders through wearable neuromodulation products.  The Company’s initial product, the Phoenix™, provides transcutaneous vagal nerve stimulation (tVNS) to treat PTSD in an effective, discreet earbud design.

CONTACT:

M. Blythe Karow

Evren Technologies, Inc.

President & COO

352.533.3381 x702

blythe.karow@evrenvns.com